{
  "trial_id": "NCT00182091",
  "overall_assessment": "likely_eligible",
  "inclusion": [
    {
      "criterion": "Age 18-75",
      "label": "met",
      "evidence": "unknown"
    },
    {
      "criterion": "History of acromegaly with biochemical cure documented with a normal oral glucose tolerance test (OGTT) and/or a non-elevated IGF-I without concurrent use of somatostatin analogs, dopamine agonists or GH receptor antagonists.",
      "label": "met",
      "evidence": "unknown"
    },
    {
      "criterion": "At the time of enrollment a minimum of 6 months must have elapsed since surgery.",
      "label": "met",
      "evidence": "unknown"
    },
    {
      "criterion": "No malignancy on colonoscopy performed since the diagnosis of acromegaly",
      "label": "met",
      "evidence": "unknown"
    },
    {
      "criterion": "GHD due to surgical or radiation treatment",
      "label": "met",
      "evidence": "unknown"
    },
    {
      "criterion": "GHD will be defined as a peak plasma GH of less than 5 ng/ml in response to an insulin tolerance test or a GH-releasing hormone (GHRH) plus arginine stimulation test",
      "label": "met",
      "evidence": "unknown"
    },
    {
      "criterion": "GHD will also be diagnosed if IGF-I levels are below 2 standard deviations for the age-sex normal range in a patient with at least two other documented anterior pituitary hormone deficiencies",
      "label": "met",
      "evidence": "unknown"
    }
  ],
  "exclusion": [
    {
      "criterion": "Untreated thyroid or adrenal insufficiency. Subjects on replacement therapy must be stable for at least 3 months prior to entry into the study",
      "label": "not_met",
      "evidence": "unknown"
    },
    {
      "criterion": "History of malignancy except for non-melanoma skin cancer",
      "label": "met",
      "evidence": "unknown"
    },
    {
      "criterion": "Hemoglobin <11.0 gm/dl",
      "label": "not_met",
      "evidence": "unknown"
    },
    {
      "criterion": "Uncontrolled hypertension",
      "label": "not_met",
      "evidence": "unknown"
    },
    {
      "criterion": "Hepatic or renal disease (aspartate aminotransferase (AST) or alanine aminotransferase (ALT) > 3x upper limit of normal (ULN) or creatinine level >2.5 mg/dl)",
      "label": "not_met",
      "evidence": "unknown"
    },
    {
      "criterion": "Congestive heart failure (New York Heart Association's classification system Class II-IV congestive heart failure (CHF) will be excluded)",
      "label": "met",
      "evidence": "unknown"
    },
    {
      "criterion": "Unstable cardiovascular disease (coronary artery or cerebrovascular disease) or symptoms within one year prior to entry into the study",
      "label": "not_met",
      "evidence": "unknown"
    }
  ],
  "notes": "Patient has history of acromegaly and biochemical cure. She is on stable doses of octreotide LAR since her diagnosis was confirmed.",
  "_meta": {
    "topic_id": "20",
    "trial_id": "NCT00182091",
    "model": "llama3.1:8b",
    "run_tag": "llama31_8b_full_top100",
    "top_k": 100
  }
}